 |
|
Compound has potential for new class of AIDS drugs
May 15, 2008ANN ARBOR, Mich.-Researchers have developed what they believe is the first new mechanism in nearly 20 years for inhibiting a common target used to treat all HIV patients, which could eventually lead to a new class of AIDS drugs.
Researchers at the University of Michigan used computer models to develop the inhibiting compound, and then confirmed in the lab that the compound does indeed inhibit HIV protease, which is an established target for AIDS treatment. The protease is necessary to replicate the virus, says Heather Carlson, U-M professor of medicinal chemistry and principal investigator of the study.
Carlson stresses this is a preliminary step, but still significant.
"It's very easy to make an inhibitor, (but) it's very hard to make a drug," said Carlson, who also has an appointment in chemistry. "This compound is too weak to work in the human body. The key is to find more compounds that will work by the same mechanism."
What's so exciting is how differently that mechanism works from the current drugs used to keep the HIV from maturing and replicating, she says. Current drugs called protease inhibitors work by debilitating the HIV-1 protease. This does the same, but in a different way, Carlson says.
A protease is an enzyme that clips apart proteins, and in the case of HIV drugs, when the HIV-1 protease is inhibited it cannot process the proteins required to assemble an active virus. In existing treatments, a larger molecule binds to the center of the protease, freezing it closed.
The new mechanism targets a different area of the HIV-1 protease, called the flap recognition pocket, and actually holds the protease open. Scientists knew the flaps opened and closed, but didn't know how to target that as a mechanism, Carlson says.
Carlson's group discovered that this flap, when held open by a very small molecule-half the size of the ones used in current drug treatments-also inhibits the protease.
In addition to a new class of drugs, the compound is key because smaller molecules have better drug-like properties and are absorbed much more easily.
"This new class of smaller molecules could have better drug properties (and) could get around current side effects," Carlson said. "HIV dosing regimes are really difficult. You have to take medicine several times in the day. Maybe you wouldn't have to do that with these smaller molecules because they would be absorbed differently."
Kelly Damm, a former student and now at Johnson & Johnson, initially had the idea to target the flaps in this new way, Carlson says.
"In a way, this works like a door jam. If you looked only at the door when it's shut, you'd not know you could put a jam in it," she said. "We saw a spot where we could block the closing event, but because everyone else was working with the closed form, they couldn't see it."
University of Michigan
"It's very easy to make an inhibitor, (but) it's very hard to make a drug," said Carlson, who also has an appointment in chemistry. "This compound is too weak to work in the human body. The key is to find more compounds that will work by the same mechanism."
What's so exciting is how differently that mechanism works from the current drugs used to keep the HIV from maturing and replicating, she says. Current drugs called protease inhibitors work by debilitating the HIV-1 protease. This does the same, but in a different way, Carlson says.
A protease is an enzyme that clips apart proteins, and in the case of HIV drugs, when the HIV-1 protease is inhibited it cannot process the proteins required to assemble an active virus. In existing treatments, a larger molecule binds to the center of the protease, freezing it closed.
The new mechanism targets a different area of the HIV-1 protease, called the flap recognition pocket, and actually holds the protease open. Scientists knew the flaps opened and closed, but didn't know how to target that as a mechanism, Carlson says.
Carlson's group discovered that this flap, when held open by a very small molecule-half the size of the ones used in current drug treatments-also inhibits the protease.
In addition to a new class of drugs, the compound is key because smaller molecules have better drug-like properties and are absorbed much more easily.
"This new class of smaller molecules could have better drug properties (and) could get around current side effects," Carlson said. "HIV dosing regimes are really difficult. You have to take medicine several times in the day. Maybe you wouldn't have to do that with these smaller molecules because they would be absorbed differently."
Kelly Damm, a former student and now at Johnson & Johnson, initially had the idea to target the flaps in this new way, Carlson says.
"In a way, this works like a door jam. If you looked only at the door when it's shut, you'd not know you could put a jam in it," she said. "We saw a spot where we could block the closing event, but because everyone else was working with the closed form, they couldn't see it."
University of Michigan
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Secondhand Smoke Beta Cells life on Mars Hubble Space Telescope Archaea Radiation Treatment Enzymes Amputation Ecosystem Cosmic Rays Ecosystems Biomarkers Multiple Myeloma Morphine Saturns Rings Leukaemia Bipolar Disorder AIDS vaccine Explosives Mangrove Palliative Care Neutron Aurora Cancer Cells Cancer Therapy
See More: Science News Tags
Protease Current Events and Protease News RSSNew study reveals structure of the HIV protein shell
New research by scientists at The Scripps Research Institute and other institutions provides a close-up look at the cone-shaped shell that is the hallmark of human immunodeficiency virus (HIV), revealing how it is held together-and possible ways to break it apart.
What is the role of reactive oxygen species in ethanol-mediated cell death of polarized hepatic cells?
Liver disease that results as a consequence of alcohol abuse is a major medical problem worldwide. Ethanol consumption leads to a variety of liver alterations including the accumulation of fat, inflammation of the liver, as well as the presence of scar tissue.
NEJM Study Points to New Era in Hepatitis C Treatment
For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.
Enzyme involved in inflammatory bowel disease discovered at Penn State College of Medicine
Researchers at Penn State College of Medicine, working with biochemists, geneticists and clinicians at the University of Bern, Switzerland and in the United Kingdom, have discovered an enzyme that has a key role in inflammatory bowel disease (IBD).
Mayo Clinic researchers find agents that speed up destruction of proteins linked to Alzheimer's
Taking a new approach to the treatment and prevention of Alzheimer's disease, a research team led by investigators at the Mayo Clinic campus in Florida has shown that druglike compounds can speed up destruction of the amyloid beta (A-beta) proteins that form plaque in the brains of patients with the disorder.
Locking Parasites in Host Cell Could Be New Way to Fight Malaria, Penn Study Shows
Researchers at the University of Pennsylvania have discovered that parasites hijack host-cell proteins to ensure their survival and proliferation, suggesting new ways to control the diseases they cause.
HIV-1 protease inhibitor induced oxidative stress in pancreatic B-cells: thymoquinone protection
Researchers at the Tulane University School of Medicine, New Orleans, Louisiana have discovered that the HIV-1 protease inhibitors (PIs), such as nelfinavir included in highly active antiretroviral therapy (HAART) regimen for the treatment of HIV-1 patients, induce deleterious effects on insulin secretion mediated through the oxidative stress pathway.
Cathepsin B increases apoptosis in fulminant hepatic failure
The traditional view is that hepatocyte necrosis is the main feature of fulminant hepatic failure, but increasing evidence implicates a dominant role for hepatocyte apoptosis in this pathogenesis.
New Stanford list of HIV mutations vital to tracking AIDS epidemic
In a collaborative study with the World Health Organization and seven other laboratories, researchers at the Stanford University School of Medicine have compiled a list of 93 common mutations of the AIDS virus associated with drug resistance that will be used to track future resistance trends throughout the world.
New information points to safer methadone use for treatment of pain and addiction
New findings may significantly improve the safety of methadone, a drug widely used to treat cancer pain and addiction to heroin and other opioid drugs, according to researchers at Washington University School of Medicine in St. Louis and the University of Washington in Seattle.
More Protease Current Events and Protease News Articles
 |
Houston Nutraceuticals Peptizyde Multiple Protease 90 Vegetable Capsules by Houston Nutraceuticals Peptizyde (pronounced "Pep-ta-zyde") is a combination of three different proteolytic enzymes isolated from plant sources. Each enzyme has a unique set of peptide bonds it prefers to break, so the combination of these enzymes allows much more efficient means of quickly and thoroughly breaking down (hydrolyzing) proteins to its smaller components. The enzymes in Peptizyde work only on food proteins, not carbohydrates, fats, or other compounds, and do not interfere with medications or other supplements (unless they are also proteins, which is extremely unlikely). Peptizyde may be used in combination with other enzyme products. Peptizyde supplements the "normal" hydrolysis of casein, gluten, and other food proteins such that the exorphin peptides are not produced because the specific cleavage... |
|
Innovations in Proteases and Their Inhibitors by Francesc X. Aviles (Author) | |
 |
Proteases in Gastrointestinal Tissues (Proteases in Biology and Disease) by Springer This book is unique for its comprehensive presentation of protease function in stomach, colon, pancreas and liver under both physiological conditions and major diseases manifesting in these four organs. The individual chapters have been written by leaders in the field who paid much attention to outline in great detail the role of proteases in the pathogenesis, diagnosis and treatment of disease. Available animal models (of disease, transgenic, or knock-out) are extensively referred to and experimental data obtained thereby are discussed in the context of patient-derived data. Newcomers to the field and interested non-specialists will take advantage of the extensive introduction to individual proteases, protease families, and the diseases. Understanding is greatly facilitated... |
 |
Digestive Enzymes 500 mg, 240 Caps by Source Naturals Digestive Aid Enzyme Supplement Each capsule contains 500 mg of an all-vegetarian, broad spectrum blend of digestive enzymes. |
 |
Proteases in Gastrointestinal Tissues (Proteases in Biology and Disease) by Uwe Lendeckel (Editor), Nigel M. Hooper (Editor) This book is unique for its comprehensive presentation of protease function in stomach, colon, pancreas and liver under both physiological conditions and major diseases manifesting in these four organs. The individual chapters have been written by leaders in the field who paid much attention to outline in great detail the role of proteases in the pathogenesis, diagnosis and treatment of disease. Available animal models (of disease, transgenic, or knock-out) are extensively referred to and experimental data obtained thereby are discussed in the context of patient-derived data. Newcomers to the field and interested non-specialists will take advantage of the extensive introduction to individual proteases, protease families, and the diseases. Understanding is greatly facilitated... |
 |
PROTEASE PLUS (90) by Nature's Sunshine Herbal Products Protease Plus provides supplemental protease enzymes that break down proteins into smaller proteins and amino acids, maximizing digestion. As we grow older, our bodies produce fewer enzymes. When a suboptimal level of protease enzyme exists, undigested proteins can pass through the intestinal tract and remain undigested. These have been linked to effects on overall health and vitality. Protease Plus may support immunity by possibly activating macrophages and natural killer cells. NSP's formula provides a full spectrum of plant-derived trace minerals, which help activate enzymes. Each capsule of NSP Protease Plus contains 60,000 HUT protease in a base of beet root fiber and plant-sourced trace mineral concentrate. Take 1 capsule with a meal three times daily for protein digestion.... |
|
Proteases: New Perspectives by Birkhauser This book provides an account of the recent advances in our understanding of the role of proteases under physiological and pathological conditions. It reviews the contributions that have been made in the fields of biochemistry, molecular biology, medicine, agriculture and ecology. In addition there is an account of the growing number of practical applications in biotechnology, reflecting the fact that peptidases are major targets for medical and agricultural purposes. The book shows how the numerous protease structures are essential for drug design. The contributions place special emphasis on cysteine, aspartic and metalloproteases and their role in physiological and certain pathological states. Another focus is the classification and nomenclature of peptidases and a review of those... | |
 |
Digestive Enzymes for Bloated Stomach with Ginger Root, Clove, Fennel Seed, Peppermint, Acid Stable Protease These DIGESTIVE ENZYMES are for abdominal bloating, gas, belching, indigestion, fatigue, irregularity, constipation, lack of energy, irritable bowels, flatulence, heartburn, tiredness, and other digestive problems. |
|
Proteases: Potential Role in Health and Disease (Advances in Experimental Medicine and Biology) by Germany) International Symposium on Proteases: Potential Role in Health and Disease (1982 : Wu¨rzburg (Author), Walter H. Horl (Author), August Heidland (Author) | |
 |
Charlie Rose with Forrest Sawyer; Ellen Barkin; Larry Kramer (January 18, 1995) ABC News journalist Forrest Sawyer talks about his new program Day One, his ascent as a journalist, and the competitive world of network television. Then, Ellen Barkin discusses her new film Bad Company, co-starring Laurence Fishburne, her background, and her long and prolific career as an actor. Finally, Larry Kramer on AIDS and the American response to the epidemic. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
| © 2009 BrightSurf.com |